ReviewAnnals of medicine and surgery (2012)2025
Acute myocardial infarction and antiphospholipid syndrome: an updated systematic review and meta-analysis.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiac arrest due to ST-elevation myocardial infarction in young woman with antiphospholipid syndrome on combined oral contraceptives.Journal of cardiology cases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antiphospholipid syndrome (APS) is an autoimmune condition associated with an increased risk of thrombosis, myocardial infarction, strokes, recurrent miscarriages, and other cardiovascular events. Acute myocardial infarction (AMI) is a severe, potentially fatal, but yet uncommon complication of APS. This comprehensive systematic review, the largest to date, aims to explore the occurrence, clinical presentations, and outcomes of AMI in individuals with APS from inception to March 2025, highlighting the evolution of management and outcomes over time. Methods: We searched through PubMed, Scopus, Web of Science, and Cochrane Central Register from inception to March 2025 in order to find case studies, series, and reports of AMI in individuals diagnosed with APS. Data were analysed quantitatively with continuous variables presented as means ± standard deviations and categorical data as frequencies or percentages. Results: Our review included 108 cases of AMI complicating APS, with 47 cases of primary APS, and 60 cases to secondary APS due to systemic lupus erythematosus. The average age at diagnosis was 36.37 ± 13.95 years. Among subjects, 36 had no history of thromboembolic events (challenging the assumption that previous thrombosis predicts cardiac complications), 34 had deep vein thrombosis, and 10 experienced cardiac-related thromboembolic events. The most common presentation of AMI in subjects with APS was ST-elevation in 90 subjects (83% of cases). The median activated partial thromboplastin time was 54 s (interquartile range: 42-84 s). Thrombocytopenia was observed in 23 cases, while 11 cases had thrombocytosis. Positive results for antiphospholipid antibodies included anticardiolipin antibody in 75 cases, lupus anticoagulant in 60 cases, and anti-β2 glycoprotein I in 25 cases. The overall prognosis was favourable, with a survival rate of 93.5% (101 individuals survived), 7 deaths, and 15 recurrent AMI episodes (13.8% of cases). Conclusion: This comprehensive systematic review calls attention to the importance of considering APS as a potential risk factor for AMI, particularly in younger adults without typical cardiovascular risk factors, yet it carries a more favourable prognosis than previously thought. The findings highlight the high prevalence of thrombotic events, emphasise the importance of considering APS in young individuals with AMI, and suggest favourable outcomes in APS-associated AMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.